About Ionis Pharmaceuticals, Inc.
https://www.ionispharma.comIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
CEO
Brett P. Monia
Compensation Summary
(Year 2024)
Salary $1,008,898
Bonus $1,024,662
Stock Awards $5,627,878
Option Awards $3,004,746
All Other Compensation $52,889
Total Compensation $15,400,343
Industry Biotechnology
Sector Healthcare
Went public May 17, 1991
Method of going public IPO
Full time employees 1,069
ETFs Holding This Stock
Summary
Total 192
Showing Top 3 of 192
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Raymond James
Strong Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Needham
Buy
TD Cowen
Buy
Guggenheim
Buy
Grade Summary
Strong Buy 1
Buy 7
Outperform 4
Overweight 5
Neutral 2
Hold 1
Showing Top 6 of 20
Price Target
Target High $100
Target Low $65
Target Median $94.5
Target Consensus $87.36
Institutional Ownership
DLD ASSET MANAGEMENT, LP
Shares:25M
Value:$1.97B
FMR LLC
Shares:23.69M
Value:$1.87B
VANGUARD GROUP INC
Shares:16.48M
Value:$1.3B
Summary
% Of Shares Owned 105.38%
Total Number Of Holders 549
Showing Top 3 of 549
Market Cap $12.96 B
52w High $86.15
52w Low $23.95
P/E -48.99
Volume 2.02M
Outstanding Shares 158.91M
About Ionis Pharmaceuticals, Inc.
https://www.ionispharma.comIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $156.72M ▼ | $314.56M ▲ | $-128.61M ▼ | -82.06% ▼ | $-0.8 ▼ | $-94.38M ▼ |
| Q2-2025 | $452.05M ▲ | $308.08M ▲ | $123.55M ▲ | 27.33% ▲ | $0.78 ▲ | $150.23M ▲ |
| Q1-2025 | $131.61M ▼ | $276.97M ▼ | $-146.94M ▼ | -111.64% ▼ | $-0.93 ▼ | $-120M ▼ |
| Q4-2024 | $226.58M ▲ | $333.57M ▲ | $-104.35M ▲ | -46.05% ▲ | $-0.66 ▲ | $-80.5M ▲ |
| Q3-2024 | $133.81M | $281.4M | $-140.48M | -104.98% | $-0.95 | $-117.38M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.24B ▼ | $3.03B ▲ | $2.42B ▲ | $617.97M ▼ |
| Q2-2025 | $2.29B ▲ | $2.99B ▲ | $2.35B ▲ | $631.72M ▲ |
| Q1-2025 | $2.15B ▼ | $2.81B ▼ | $2.34B ▼ | $475.73M ▼ |
| Q4-2024 | $2.3B ▼ | $3B ▼ | $2.42B ▼ | $588.35M ▼ |
| Q3-2024 | $2.48B | $3.08B | $2.42B | $662.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-128.61M ▼ | $-131.44M ▼ | $91.34M ▲ | $81.22M ▲ | $41.04M ▲ | $-134.74M ▼ |
| Q2-2025 | $123.55M ▲ | $151.34M ▲ | $-120.07M ▼ | $1.25M ▼ | $33.11M ▲ | $137.07M ▲ |
| Q1-2025 | $-146.94M ▼ | $-150.78M ▼ | $170.46M ▲ | $2.2M ▲ | $22.11M ▲ | $-163.35M ▼ |
| Q4-2024 | $-104.35M ▲ | $-116.14M ▼ | $68.21M ▲ | $-44.12M ▼ | $-92.53M ▼ | $-141.64M ▼ |
| Q3-2024 | $-140.48M | $-114.99M | $-340.8M | $496.05M | $40.61M | $-124.05M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Collaborative Agreement Revenue | $40.00M ▲ | $150.00M ▲ | $0 ▼ | $50.00M ▲ |
 Commercial | $80.00M ▲ | $150.00M ▲ | $0 ▼ | $80.00M ▲ |
 Commercial Member | $0 ▲ | $0 ▲ | $100.00M ▲ | $0 ▼ |
 Other Commercial | $10.00M ▲ | $30.00M ▲ | $0 ▼ | $10.00M ▲ |
 Product | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ | $0 ▼ |
 Product Sales Net | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Research and Development Revenue | $60.00M ▲ | $200.00M ▲ | $0 ▼ | $60.00M ▲ |
 Royalty | $0 ▲ | $0 ▲ | $70.00M ▲ | $60.00M ▼ |
 SPINRAZA Royalties | $60.00M ▲ | $100.00M ▲ | $0 ▼ | $50.00M ▲ |
 TEGSEDI and WAYLIVRA | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Licensing and Other Royalties | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Brett P. Monia
Compensation Summary
(Year 2024)
Salary $1,008,898
Bonus $1,024,662
Stock Awards $5,627,878
Option Awards $3,004,746
All Other Compensation $52,889
Total Compensation $15,400,343
Industry Biotechnology
Sector Healthcare
Went public May 17, 1991
Method of going public IPO
Full time employees 1,069
ETFs Holding This Stock
Summary
Total 192
Showing Top 3 of 192
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Raymond James
Strong Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
Needham
Buy
TD Cowen
Buy
Guggenheim
Buy
Grade Summary
Strong Buy 1
Buy 7
Outperform 4
Overweight 5
Neutral 2
Hold 1
Showing Top 6 of 20
Price Target
Target High $100
Target Low $65
Target Median $94.5
Target Consensus $87.36
Institutional Ownership
DLD ASSET MANAGEMENT, LP
Shares:25M
Value:$1.97B
FMR LLC
Shares:23.69M
Value:$1.87B
VANGUARD GROUP INC
Shares:16.48M
Value:$1.3B
Summary
% Of Shares Owned 105.38%
Total Number Of Holders 549
Showing Top 3 of 549